Skip to main content
ELAB
NASDAQ Life Sciences

PMGC Ends Arizona Acquisition LOI, Inks Orbit2Orbit Space Partnership Term Sheet

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$5.8
Mkt Cap
$4.72M
52W Low
$5.24
52W High
$2,671.2
52W Position info
11% above low
Off High info
100% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

ELAB is trading near its 52-week low of $5.24 (11% above the low) on light trading volume (0.1× avg).

Summary

PMGC terminated its LOI to acquire a 76% stake in an Arizona machining company after due diligence, and signed a non-binding term sheet with Orbit2Orbit for a space research, manufacturing, and investment partnership. The filing also discloses a $1.07M debt-for-equity exchange with Streeterville and confirms the 1-for-10 reverse split.


Key Events · M&A and Partnerships · ELAB

  • Arizona Acquisition LOI Terminated

    PMGC terminated its non-binding LOI to acquire a 76% stake in an Arizona precision machining company after audit-stage due diligence showed the target's historical financial profile was less favorable than anticipated. No breakup fee was incurred.

  • Orbit2Orbit Term Sheet Signed

    Non-binding term sheet with Orbit2Orbit Inc. contemplates three transactions: a Mice2Space microgravity research collaboration for EL-22/EL-32, a preferred U.S. manufacturing role for A&B Aerospace, and a CAD $200,000 investment at CAD $0.80 per share.

  • Streeterville Debt-for-Equity Exchange

    Exchange Agreement converts $1,071,339.80 of Secured Pre-Paid Purchase #2 into 80,000 shares of common stock, reducing cash obligations but adding dilution. Company retains a repurchase right at $0.0001 per share once the balance is zero.

  • 1-for-10 Reverse Split Effective

    Reverse split effective August 21, 2026 reduced authorized common shares to 8,333,334 (plus 500,000,000 preferred). Trading symbol ELAB unchanged; new CUSIP 73017P607 assigned.


Analysis · ELAB · Life Sciences

After audit-stage due diligence revealed a weaker historical financial profile than expected, PMGC Holdings walked away from its previously announced acquisition of a 76% stake in an Arizona precision machining company. The termination signals capital allocation discipline but also removes a growth catalyst announced just three months ago. In its place, the company signed a non-binding term sheet with Orbit2Orbit for a three-part space economy relationship — a microgravity research collaboration for its EL-22/EL-32 muscle-preservation candidates, a preferred U.S. manufacturing role for A&B Aerospace, and a CAD $200,000 strategic investment. The filing also discloses a debt-for-equity exchange with Streeterville Capital converting $1.07 million of secured pre-paid purchase obligations into 80,000 shares, and confirms the 1-for-10 reverse split effective August 21. Against a backdrop of a $7.9M H1 net loss and going concern warning from the August 14 10-Q, the Streeterville exchange reduces cash obligations but adds dilution, while the Orbit2Orbit term sheet is non-binding and may not close.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ELAB was trading at $5.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7M. The 52-week trading range was $5.24 to $2,671.20. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ELAB - Latest Insights

ELAB
Nov 16, 2026, 7:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.63
Real-time Price: $1.45 info
Change: -$0.1807 (-11%) info
Market Cap: $1.174M info
ELAB
Nov 13, 2026, 4:00 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.58
Real-time Price: $1.45 info
Change: -$0.130 (-8%) info
Market Cap: $1.174M info
ELAB
Nov 02, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.12
Real-time Price: $1.45 info
Change: -$0.670 (-32%) info
Market Cap: $1.174M info
ELAB
Oct 01, 2026, 8:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $3.62
Real-time Price: $1.45 info
Change: -$2.17 (-60%) info
Market Cap: $1.174M info
ELAB
Sep 18, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.70
Real-time Price: $1.45 info
Change: -$3.25 (-69%) info
Market Cap: $1.174M info